Zentalis Pharmaceuticals, Inc. Common Stock (ZNTL) is a publicly traded Healthcare sector company. As of October 19, 2026, ZNTL trades at $2.23 with a market cap of $201.65M and a P/E ratio of -1.30. ZNTL moved -4.02% today. Year to date, ZNTL is +57.78%; over the trailing twelve months it is +36.54%. Its 52-week range spans $1.01 to $6.95. Analyst consensus is strong buy with an average price target of $8.14. Rallies surfaces ZNTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks ZNTL insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $2.23 |
| Market Cap | $201.65M |
| P/E Ratio | -1.30 |
| EPS | $-1.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.95 |
| 52-Week Low | $1.01 |
| Volume | 1.03M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-137.06M |
| Gross Margin | 0.00% |
8 analysts cover ZNTL: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.14.